A potential antitumor peptide therapeutic derived from antineoplastic urinary protein.
New therapies in cancer treatment are focusing on multifaceted approaches to starve and kill tumors utilizing both antiangiogenic and chemotherapeutic compounds. Antineoplastic Urinary Protein (ANUP), a 32k Da protein normally secreted in human urine, has been previously described as a molecule possessing both antiproliferative and antiangiogenic activities. Two synthetic peptides complimentary to the N-terminus of ANUP were designed to test their ability to reproduce these beneficial effects but ultimately to provide a more useful small molecule therapeutic. The results show that the peptides reduced tumor burden by up to 70% in a nude mouse model and demonstrated the ability to inhibit blood vessel formation in a chick chorioallantoic membrane assay (CAM).
Hehir
Kathleen M
KM
TranXenoGen Inc., Technology Development, 800 Boston Turnpike, Shrewsbury, MA 01545, USA. khehir@tranxenogen.com
Baguisi
Alexander
A
Pennington
Sarah E
SE
Bates
Janna M
JM
DiTullio
Paul A
PA
D000818:Animals; D000950:Antigens, Ly / Q000008:administration & dosage*; D002642:Chick Embryo; D017281:Cost of Illness; D005260:Female; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000473:pathology; D010455:Peptides / Q000008:administration & dosage*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D000950:Antigens, Ly; D010455:Peptides; C048963:SLURP1 protein, human; D014568:Urokinase-Type Plasminogen Activator